KIMS Hospitals Q3 FY26: Revenue Up 29.2% to ₹997.7 Crore, EBITDA Margins at 20.4%
Krishna Institute of Medical Sciences Limited (KIMS) reported Q3 FY26 operating revenue of ₹997.7 crore, up 29.2% YoY. Nine-month revenue increased 25.6% to ₹2,846.5 crore. Q3 EBITDA was ₹204.1 crore (down 0.4% YoY) with margins at 20.4%. Operational metrics showed growth, with IP volume up 13.2% and OP volume up 24.5%.
The announcement provides detailed financial results and operational updates, which are important for investors. The strong revenue growth is a key positive factor, but the slight dip in EBITDA margins and the lack of specific forward guidance moderate the impact.
The company reported strong year-on-year revenue growth, indicating positive business performance and expansion. While EBITDA margins saw a slight contraction, the overall revenue increase and operational growth metrics suggest a positive outlook.
Krishna Institute of Medical Sciences Limited (KIMS) announced its unaudited financial results for the third quarter and nine months ended December 31, 2025. The company reported a significant year-on-year increase in operating revenue, which grew by 29.2% to ₹9,977 million (₹997.7 crore) in Q3 FY26, compared to ₹7,724 million (₹772.4 crore) in Q3 FY25.
For the nine-month period ended December 31, 2025, total revenue stood at ₹28,465 million (₹2,846.5 crore), a 25.6% increase from ₹22,655 million (₹2,265.5 crore) in the same period last year. However, EBITDA for Q3 FY26 saw a slight decrease of 0.4% year-on-year to ₹2,041 million (₹204.1 crore), with EBITDA margins contracting to 20.4% from 25.9% in Q3 FY25. For the nine-month period, EBITDA remained flat at ₹6,120 million (₹612 crore).
Operational highlights for Q3 FY26 included a 13.2% increase in In-Patient (IP) volume to 61,139 and a 24.5% rise in Out-Patient (OP) volume to 585,491. Average Revenue Per Operating Bed (ARPOB) increased by 20.5% to ₹46,341, and Average Revenue Per Patient (ARPP) rose by 13.9% to ₹164,232.
The company also provided details on its expansion and ramp-up of units across various regions, including Kerala, Maharashtra, Andhra Pradesh, and Karnataka, highlighting new services, technological advancements, and bed capacity additions. KIMS continues to focus on strategic doctor partnerships and regional market leadership to drive future growth.
What to do with a filing like this
Krishna Institute of Medical Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krishna Institute of Medical Sciences Limited. Read the original for the full detail.